A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy

Kiran Devisetty; Loren K Mell; Joseph K Salama; David A Schomas; Robert C Miller; Ashesh B Jani; John C Roeske; Bulent Aydogan; Steven J Chmura

doi:10.1016/j.radonc.2009.07.006

A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy

Radiother Oncol. 2009 Nov;93(2):298-301. doi: 10.1016/j.radonc.2009.07.006. Epub 2009 Aug 28.

Authors

Kiran Devisetty¹, Loren K Mell, Joseph K Salama, David A Schomas, Robert C Miller, Ashesh B Jani, John C Roeske, Bulent Aydogan, Steven J Chmura

Affiliation

¹ Department of Radiation and Cellular Oncology, University of Chicago, IL, USA.

PMID: 19717198
DOI: 10.1016/j.radonc.2009.07.006

Abstract

Using previous dosimetric analysis methods, we identified the volume of bowel receiving 30 Gy (V(30)) correlated with acute gastrointestinal (GI) toxicity in anal cancer patients treated with intensity-modulated radiation therapy and concurrent chemotherapy. For V(30)>450 cc and < or =450 cc, acute GI toxicity was 33% and 8%, respectively (p=0.003).

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Anus Neoplasms / therapy*
Combined Modality Therapy
Female
Fluorouracil / administration & dosage
Gastrointestinal Tract / drug effects*
Gastrointestinal Tract / radiation effects*
Humans
Male
Middle Aged
Mitomycin / administration & dosage
Radiotherapy, Intensity-Modulated / adverse effects*

Substances

Mitomycin
Fluorouracil